首页 > 市场调查报告书 > 製药

基因治疗学和RNAi

市场调查报告书

商品编码

1517714

细胞转染市场 - 全球产业规模、份额、趋势、机会和预测，按方法、最终用户、地区和竞争细分，2019-2029F

Cell Transfection Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Method, By End User, By Region and Competition, 2019-2029F

出版日期: 2024年07月21日 | 出版商:

TechSci Research | 英文 189 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年全球细胞转染市场价值为13.2 亿美元，预计在预测期内将强劲增长，到2029 年复合年增长率为8.68%。显着的成长和创新在生物技术领域，细胞治疗和基因治疗的研究活动不断增加，以及对将核酸有效输送到细胞的需求不断增长。细胞转染是一种将外源遗传物质引入细胞的技术，在学术研究、药物发现和开发、癌症治疗和再生医学等各种应用中发挥着至关重要的作用。此市场包含各种适合不同细胞类型和应用的转染试剂、仪器和方法。

市场概况
预测期	2025-2029
2023 年市场规模	13.2亿美元
2029 年市场规模	21.5亿美元
2024-2029 年复合年增长率	8.68%
成长最快的细分市场	电穿孔
最大的市场	北美洲

市场成长的关键驱动力之一是癌症和遗传性疾病等慢性疾病的盛行率不断上升，推动了对利用细胞转染技术将治疗基因传递到目标细胞中的基因治疗方法的需求。此外，公共和私营部门对生物技术和药物研发活动的投资不断增加，促进了新型转染技术的开发，提高了效率、安全性和可扩展性，从而扩大了市场机会。此外，像 CRISPR-Cas9 这样的基因组编辑技术的出现进一步推动了对能够精确、特异性地构建大型 DNA 构建体的先进转染方法的需求。从地理位置上看，北美在全球细胞转染市场中占有重要份额，这得益于完善的生物技术和製药行业、强大的研究基础设施以及促进基因组研究和个性化医疗的政府支持倡议。由于领先的生物技术公司、学术研究机构的存在以及转化研究投资的增加，欧洲也为市场成长做出了贡献。

此外，由于先进生物技术的不断采用、医疗保健支出的增加以及医疗保健专业人员和患者对基因疗法的认识不断提高，亚太地区的市场正在快速扩张。然而，市场面临基因治疗产品严格的监管要求、与基因操作相关的伦理问题以及先进转染技术的高成本等挑战，这可能会阻碍基因治疗产品的广泛采用，特别是在发展中地区。儘管如此，旨在开发下一代转染技术的持续研究工作预计将进一步推动市场成长，该技术具有提高的递送效率、降低的细胞毒性和改善的目标细胞特异性。

主要市场驱动因素

生物技术不断进步

慢性病盛行率上升

不断增加研发投资

主要市场挑战

监管障碍和合规性

道德和安全问题

成本和可及性

主要市场趋势

基因编辑技术的进步

细胞和基因疗法的兴起

细分市场洞察

方法见解

区域洞察

Global Cell Transfection Market was valued at USD 1.32 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 8.68% through 2029. The Global Cell Transfection Market has experienced significant growth and innovation in recent years, driven by advancements in biotechnology, increasing research activities in cell therapy and gene therapy, and the growing demand for efficient delivery of nucleic acids into cells. Cell transfection, a technique used to introduce foreign genetic material into cells, plays a crucial role in various applications such as academic research, drug discovery and development, cancer therapy, and regenerative medicine. The market encompasses a wide range of transfection reagents, instruments, and methods catering to diverse cell types and applications.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 1.32 Billion
Market Size 2029	USD 2.15 Billion
CAGR 2024-2029	8.68%
Fastest Growing Segment	Electroporation
Largest Market	North America

One of the key drivers of market growth is the rising prevalence of chronic diseases such as cancer and genetic disorders, propelling the demand for gene therapy approaches that utilize cell transfection techniques for delivering therapeutic genes into target cells. Additionally, the increasing investments in biotechnology and pharmaceutical R&D activities by both public and private sectors have led to the development of novel transfection technologies with improved efficiency, safety, and scalability, thereby expanding the market opportunities. Moreover, the emergence of genome editing technologies like CRISPR-Cas9 has further fueled the demand for advanced transfection methods capable of delivering large DNA constructs with precision and specificity. Geographically, North America holds a significant share in the global cell transfection market, driven by a well-established biotechnology and pharmaceutical industry, robust research infrastructure, and supportive government initiatives promoting genomic research and personalized medicine. Europe also contributes to the market growth owing to the presence of leading biotech companies, academic research institutes, and increasing investments in translational research.

Also, the Asia-Pacific region is witnessing rapid market expansion attributed to the growing adoption of advanced biotechnologies, increasing healthcare expenditure, and rising awareness about gene-based therapies among healthcare professionals and patients. However, the market faces challenges such as stringent regulatory requirements for gene therapy products, ethical concerns associated with genetic manipulation, and the high cost of advanced transfection technologies, which may hinder the widespread adoption, particularly in developing regions. Nevertheless, ongoing research efforts aimed at developing next-generation transfection technologies with enhanced delivery efficiency, reduced cytotoxicity, and improved target cell specificity are expected to drive the market growth further.

Key Market Drivers

Growing Advancements in Biotechnology

Advancements in biotechnology have been instrumental in propelling the global cell transfection market forward, driving innovation and expanding the scope of applications for this essential molecular biology technique. Biotechnology innovations have significantly enhanced the efficiency, specificity, and safety of cell transfection methods, thereby fueling their adoption in diverse research and therapeutic areas.

One key advancement is the development of novel transfection reagents and delivery systems that improve the delivery of nucleic acids into target cells. Lipid-based transfection reagents, for example, have been engineered to form stable complexes with nucleic acids, facilitating their efficient uptake by cells and minimizing cytotoxicity. These advancements have revolutionized gene transfer techniques, enabling researchers to manipulate gene expression patterns and study gene function with unprecedented precision.

Additionally, the advent of electroporation technology has revolutionized the field of cell transfection by enabling the delivery of nucleic acids into cells through the application of electric pulses. Electroporation offers high transfection efficiency and can be used with a wide range of cell types, making it a versatile tool for gene delivery in both research and therapeutic applications. Likewise, advancements in viral vector design and engineering have led to the development of safer and more efficient gene delivery vehicles for gene therapy applications, including adeno-associated viruses (AAVs) and lentiviral vectors.

Another significant advancement driving the global cell transfection market is the integration of genome editing technologies such as CRISPR-Cas9 into transfection workflows. CRISPR-Cas9 allows for precise manipulation of the genome by targeting specific DNA sequences and inducing double-strand breaks, enabling gene knockout, knock-in, and gene correction. Cell transfection techniques are essential for delivering CRISPR-Cas9 components into target cells, facilitating genome editing and opening new avenues for therapeutic intervention in genetic diseases and cancer.

Moreover, advancements in biotechnology have led to the development of sophisticated cell culture systems and 3D tissue models that better mimic the physiological environment, enhancing the relevance and predictive power of cell-based assays and drug screening platforms. These advancements have driven the demand for efficient cell transfection methods capable of delivering nucleic acids into complex cell cultures and tissue models, further fueling market growth.

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases worldwide has emerged as a significant driver of growth for the global cell transfection market. Chronic diseases such as cancer, genetic disorders, autoimmune diseases, and neurodegenerative conditions impose a substantial burden on healthcare systems and society. In response to this growing healthcare challenge, there has been an increased focus on developing innovative therapeutic strategies, including gene therapy and cell-based therapies, which rely heavily on cell transfection techniques for their efficacy.

Gene therapy holds promise for treating a wide range of chronic diseases by delivering therapeutic genes into target cells to correct genetic defects, modulate gene expression, or induce specific cellular responses. Cell transfection plays a crucial role in gene therapy by facilitating the efficient delivery of nucleic acids into patient cells, thereby enabling the expression of therapeutic proteins or RNA molecules. This approach holds immense potential for addressing the underlying causes of chronic diseases at the molecular level, offering the possibility of long-term or even curative treatments.

Moreover, the advent of cell-based therapies, such as CAR-T cell therapy for cancer and stem cell therapy for regenerative medicine, has further fueled the demand for cell transfection technologies. These therapies involve modifying patient-derived cells ex vivo through transfection with therapeutic genes or genome editing tools before reintroducing them into the patient's body to exert therapeutic effects. Cell transfection methods are essential for efficiently engineering patient cells and ensuring their safe and effective delivery back into the patient.

The increasing prevalence of cancer has been a driving force behind the growth of the cell transfection market. With cancer being one of the leading causes of morbidity and mortality worldwide, there is a pressing need for innovative treatment options that can effectively target tumor cells while minimizing harm to healthy tissues. Gene therapy approaches utilizing cell transfection techniques offer a promising avenue for developing targeted cancer therapies that exploit the unique genetic vulnerabilities of cancer cells.

Also, the growing understanding of the genetic basis of various chronic diseases has fueled research efforts aimed at developing personalized medicine approaches tailored to individual patients' genetic profiles. Cell transfection technologies play a crucial role in personalized medicine by enabling the delivery of patient-specific therapeutic agents, such as gene editing tools or RNA-based therapeutics, into target cells for precise and tailored treatments.

Growing Investments in Research and Development

Growing investments in research and development (R&D) have been a significant driving force behind the expansion of the global cell transfection market. Biotechnology and pharmaceutical companies, academic institutions, and government agencies are allocating substantial resources towards advancing cell transfection technologies, thereby driving innovation and expanding the market landscape. One of the key areas benefiting from increased R&D investment is the development of novel transfection reagents and delivery systems. Researchers are continuously striving to improve the efficiency, specificity, and safety of cell transfection methods, leading to the discovery of new transfection reagents with enhanced properties. These advancements enable more efficient delivery of nucleic acids into target cells, facilitating a wide range of applications in basic research, drug discovery, and therapeutic development.

Moreover, R&D investments are driving the development of advanced genome editing technologies, such as CRISPR-Cas9, and their integration into cell transfection workflows. CRISPR-Cas9 has revolutionized the field of molecular biology by providing a precise and efficient tool for editing the genome, enabling researchers to manipulate gene expression, correct genetic defects, and study disease mechanisms with unprecedented precision. Cell transfection techniques play a crucial role in delivering CRISPR-Cas9 components into target cells, thereby driving the demand for transfection reagents and systems capable of efficiently delivering large DNA constructs.

In addition to technology development, R&D investments are fueling the exploration of new therapeutic applications for cell transfection technologies. Gene therapy has emerged as a promising approach for treating a wide range of diseases, including genetic disorders, cancer, and infectious diseases. Researchers are leveraging cell transfection techniques to deliver therapeutic genes into patient cells, enabling the expression of therapeutic proteins or RNA molecules to correct genetic defects or modulate disease processes.

Also, the growing trend towards personalized medicine is driving R&D efforts to develop tailored cell-based therapies that are customized to individual patients' genetic profiles. Cell transfection technologies play a crucial role in this endeavor by enabling the efficient engineering of patient-derived cells ex vivo before their reintroduction into the patient's body for therapeutic purposes.

Key Market Challenges

Regulatory Hurdles and Compliance

One of the primary challenges facing the global cell transfection market is the complex regulatory landscape governing the development, approval, and commercialization of cell-based therapies and gene editing technologies. Regulatory agencies impose stringent requirements for demonstrating the safety, efficacy, and quality of cell transfection products, leading to lengthy and expensive approval processes. Additionally, the evolving nature of regulations and guidelines creates uncertainty for manufacturers and researchers, hindering investment and innovation in the market.

Ethical and Safety Concerns

Ethical considerations surrounding the use of gene editing technologies and cell-based therapies present significant challenges for the global cell transfection market. The potential for unintended genetic modifications, off-target effects, and long-term safety risks raises ethical concerns among patients, healthcare professionals, and regulatory authorities. Moreover, public perceptions of genetic manipulation and concerns about the misuse of gene editing technologies further complicate the development and adoption of cell transfection products for therapeutic applications.

Cost and Accessibility

The high cost of cell transfection reagents, instruments, and technologies poses a barrier to market adoption, particularly in developing regions with limited financial resources and healthcare infrastructure. The affordability and accessibility of cell transfection products are critical factors influencing their uptake in research laboratories, academic institutions, and clinical settings. Moreover, disparities in healthcare access and economic disparities exacerbate inequalities in the availability of cutting-edge cell transfection technologies, limiting their widespread adoption and impact.

Key Market Trends

Advancements in Gene Editing Technologies

Advancements in gene editing technologies, particularly CRISPR-Cas9, are playing a pivotal role in boosting the global cell transfection market. CRISPR-Cas9 has revolutionized molecular biology by providing a precise and efficient tool for editing the genome, enabling researchers to manipulate gene expression, correct genetic defects, and study disease mechanisms with unprecedented precision. This technology relies on the delivery of CRISPR-Cas9 components into target cells, a process facilitated by cell transfection techniques.

The emergence of CRISPR-Cas9 has expanded the applications of cell transfection methods in both basic research and therapeutic development. In research settings, CRISPR-Cas9 enables scientists to create cellular models of disease, elucidate gene function, and identify potential drug targets with unprecedented precision. Cell transfection techniques are essential for delivering CRISPR-Cas9 components, such as guide RNAs and Cas9 proteins, into target cells, allowing for precise genome editing and functional analysis.

Moreover, the application of CRISPR-Cas9 in therapeutic development has led to a surge in demand for cell transfection technologies. Gene therapy approaches utilize CRISPR-Cas9 to deliver therapeutic genes into target cells, offering promising treatments for a wide range of diseases, including genetic disorders, cancer, and infectious diseases. Cell transfection methods enable the efficient delivery of CRISPR-Cas9 components into patient cells, paving the way for the development of targeted and personalized therapies tailored to individual patients' genetic profiles.

Advancements in gene editing technologies such as CRISPR-Cas9 are driving the demand for cell transfection methods by expanding their applications in basic research, drug discovery, and therapeutic development. As CRISPR-based approaches continue to evolve and gain traction in the biomedical field, the global cell transfection market is poised for continued growth and innovation.

Rise of Cell and Gene Therapies

The rise of cell and gene therapies is significantly boosting the global cell transfection market, marking a transformative era in healthcare. Cell and gene therapies have emerged as promising approaches for treating a wide range of diseases, including genetic disorders, cancer, and autoimmune conditions. These therapies rely on cell transfection techniques to introduce therapeutic genes or edit the genome of patient-derived cells before their administration back into the patient's body.

Cell-based therapies, such as CAR-T cell therapy and stem cell therapy, harness the body's own immune or regenerative capabilities to combat diseases. Cell transfection is integral to these therapies, facilitating the modification of patient-derived cells ex vivo before their reintroduction into the patient's body. For example, in CAR-T cell therapy, T cells are genetically engineered using cell transfection techniques to express chimeric antigen receptors (CARs) that target specific antigens on cancer cells, enabling the immune system to recognize and destroy tumors.

Similarly, gene therapy approaches utilize cell transfection to deliver therapeutic genes into target cells, offering promising treatments for genetic disorders and other diseases. Cell transfection techniques enable the efficient delivery of therapeutic nucleic acids, such as plasmid DNA or viral vectors, into patient cells, allowing for the expression of therapeutic proteins or correction of genetic defects. This has led to breakthroughs in treating rare genetic diseases, such as spinal muscular atrophy and inherited retinal disorders.

The growing adoption of cell and gene therapies is driving demand for advanced cell transfection technologies, including transfection reagents, instruments, and delivery systems. As these therapies continue to advance and gain regulatory approval, the global cell transfection market is expected to expand further, offering new opportunities for innovation and growth in the biomedical field.

Segmental Insights

Method Insights

Based on the method, electroporation emerged as the dominant segment in the global cell transfection market in 2023. This dominance can be attributed to several factors that make electroporation a preferred choice for researchers and biopharmaceutical companies. Electroporation offers a highly efficient and versatile method for delivering nucleic acids into various cell types. By applying short electric pulses, electroporation creates transient pores in the cell membrane, allowing for the uptake of DNA, RNA, or proteins. This high transfection efficiency makes electroporation suitable for a wide range of applications, including gene editing, gene therapy, and protein expression.

Also, electroporation is a non-viral transfection method, which reduces the risk of immunogenicity and cytotoxicity associated with viral-based delivery systems. It is also compatible with a diverse range of cell types, including hard-to-transfect cells such as primary cells and stem cells. Additionally, electroporation offers scalability and reproducibility, making it suitable for both small-scale research studies and large-scale manufacturing processes.

Regional Insights

North America emerged as the dominant region in the global cell transfection market in 2023, holding the largest market share. The region's strong research ecosystem fosters collaboration between academia and industry, facilitating the development and commercialization of cutting-edge cell transfection products and solutions. Additionally, favorable government initiatives and policies support research and investment in biotechnology and life sciences sectors, providing financial incentives and regulatory support for companies developing cell transfection technologies.

Key Market Players

Thermo Fisher Scientific, Inc.

Promega Corporation

Lonza Group AG

QIAGEN NV

F. Hoffmann-La Roche Ltd.

Bio-Rad Laboratories Inc.

Merck KGaA,

OriGene Technologies, Inc.

MaxCyte, Inc.

Polyplus-transfection SA

Report Scope:

In this report, the Global Cell Transfection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Transfection Market, By Method:

Electroporation Lipofection Calcium Phosphate Viral Transfection Others

Cell Transfection Market, By End User:

Academic and Research Institutes Pharmaceutical and Biotechnology Companies Contract Research Organizations Others

Cell Transfection Market, By Region:

United States
Canada
Mexico

France
United Kingdom
Italy
Germany
Spain

China
India
Japan
Australia
South Korea

Brazil
Argentina
Colombia

South Africa
Saudi Arabia
UAE
Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Transfection Market.

Available Customizations:

Global Cell Transfection Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Transfection Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Method (Electroporation, Lipofection, Calcium Phosphate, Viral Transfection, Others)
- 5.2.2. By End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2023)
5.3. Market Map

6. Asia Pacific Cell Transfection Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Method
- 6.2.2. By End User
- 6.2.3. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Cell Transfection Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Method
    - 6.3.1.2.2. By End User
- 6.3.2. India Cell Transfection Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Method
    - 6.3.2.2.2. By End User
- 6.3.3. Australia Cell Transfection Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Method
    - 6.3.3.2.2. By End User
- 6.3.4. Japan Cell Transfection Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Method
    - 6.3.4.2.2. By End User
- 6.3.5. South Korea Cell Transfection Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Method
    - 6.3.5.2.2. By End User

7. Europe Cell Transfection Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Method
- 7.2.2. By End User
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Cell Transfection Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Method
    - 7.3.1.2.2. By End User
- 7.3.2. Germany Cell Transfection Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Method
    - 7.3.2.2.2. By End User
- 7.3.3. Spain Cell Transfection Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Method
    - 7.3.3.2.2. By End User
- 7.3.4. Italy Cell Transfection Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Method
    - 7.3.4.2.2. By End User
- 7.3.5. United Kingdom Cell Transfection Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Method
    - 7.3.5.2.2. By End User

8. North America Cell Transfection Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Method
- 8.2.2. By End User
- 8.2.3. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Cell Transfection Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Method
    - 8.3.1.2.2. By End User
- 8.3.2. Mexico Cell Transfection Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Method
    - 8.3.2.2.2. By End User
- 8.3.3. Canada Cell Transfection Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Method
    - 8.3.3.2.2. By End User

9. South America Cell Transfection Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Method
- 9.2.2. By End User
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Cell Transfection Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Method
    - 9.3.1.2.2. By End User
- 9.3.2. Argentina Cell Transfection Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Method
    - 9.3.2.2.2. By End User
- 9.3.3. Colombia Cell Transfection Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Method
    - 9.3.3.2.2. By End User

10. Middle East and Africa Cell Transfection Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Method
- 10.2.2. By End User
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Cell Transfection Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Method
    - 10.3.1.2.2. By End User
- 10.3.2. Saudi Arabia Cell Transfection Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Method
    - 10.3.2.2.2. By End User
- 10.3.3. UAE Cell Transfection Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Method
    - 10.3.3.2.2. By End User
- 10.3.4. Egypt Cell Transfection Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Method
    - 10.3.4.2.2. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Cell Transfection Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. Competitive Landscape

15.1. Thermo Fisher Scientific, Inc.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (In case of listed)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
15.2. Promega Corporation
15.3. Lonza Group AG
15.4. QIAGEN NV
15.5. F. Hoffmann-La Roche Ltd.
15.6. Bio-Rad Laboratories Inc.
15.7. Merck KGaA
15.8. OriGene Technologies Inc.
15.9. MaxCyte, Inc.
15.10. Polyplus-transfection SA

16. Strategic Recommendations

17. About Us & Disclaimer

02-2729-4219

+886-2-2729-4219

License/价格

细胞转染市场 - 全球产业规模、份额、趋势、机会和预测，按方法、最终用户、地区和竞争细分，2019-2029F

Cell Transfection Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Method, By End User, By Region and Competition, 2019-2029F

主要市场驱动因素

主要市场挑战

主要市场趋势

细分市场洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球细胞转染市场展望

第 6 章：亚太细胞转染市场展望

第 7 章：欧洲细胞转染市场展望

第 8 章：北美细胞转染市场展望

第 9 章：南美洲细胞转染市场展望

第 10 章：中东和非洲细胞转染市场展望

第 11 章：市场动态

第 12 章：市场趋势与发展

第 13 章：全球细胞转染市场：SWOT 分析

第 14 章：波特的五力分析

第15章：竞争格局

第 16 章：策略建议

第17章调查会社について・免责事项

Report Scope:

Cell Transfection Market, By Method:

Cell Transfection Market, By End User:

Cell Transfection Market, By Region:

Competitive Landscape

Available Customizations:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Cell Transfection Market Outlook

6. Asia Pacific Cell Transfection Market Outlook

7. Europe Cell Transfection Market Outlook

8. North America Cell Transfection Market Outlook

9. South America Cell Transfection Market Outlook

10. Middle East and Africa Cell Transfection Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Global Cell Transfection Market: SWOT Analysis

14. Porter's Five Forces Analysis

15. Competitive Landscape

16. Strategic Recommendations

17. About Us & Disclaimer